BioXCell最新文献引用

neobioscience 发表于 2021-11-1 17:13:51 | 显示全部楼层 |阅读模式
Nature Communications最新发布的文献 ”Contrast-enhanced ultrasound with sub-micron sized contrast agents detects insulitis in mouse models of type1 diabetes” 使用了BioXCell的InVivoPlus anti-mouse CD4(Clone: GK1.5)抗体, 揭示了使用亚微米级造影剂的超声造影检测I型糖尿病小鼠模型中的胰岛素炎。
CgAH6GCLvOOAO8soAAEiOrwo1ZE541.png
摘要:In type1 diabetes (T1D) autoreactive T-cells infiltrate the islets of Langerhans, depleting insulin-secreting β-cells (insulitis). Insulitis arises during an asymptomatic phase, prior to clinical diagnosis of T1D. Methods to diagnose insulitis and β-cell mass changes during this asymptomatic phase are limited, precluding early therapeutic intervention. During T1D the islet microvasculature increases permeability, allowing nanoparticles to access the microenvironment. Contrast enhanced ultrasound (CEUS) uses shell-stabilized gas bubbles to provide acoustic backscatter in vasculature. Here, we report that sub-micron sized ‘nanobubble’ ultrasound contrast agents can be used to measure increased islet microvasculature permeability and indicate asymptomatic T1D. Through CEUS and histological analysis, pre-clinical models of T1D show accumulation of nanobubbles specifically within pancreatic islets, correlating with insulitis. Importantly, accumulation is detected early in disease progression and decreases with successful therapeutic intervention. Thus, sub-micron sized nanobubble ultrasound contrast agents provide a predicative marker for disease progression and therapeutic reversal early in asymptomatic T1D.

CgAH6GCLvRmAWthsAAWiJkobY_o789.png
文章链接:www.nbs-bio.com/xwzx_832.html

本文仅供参考~

全部回复1 显示全部楼层

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

注册会员
  • 发布

  • 回复

  • 积分

    180

返回列表